跳轉至內容
Merck
全部照片(1)

重要文件

SML1916

Sigma-Aldrich

马里佐米

≥95% (HPLC), (Salinospora tropica)

同義詞:

(1R,4R,5S)-4-(2-氯乙基)-1-[(S)-(1S)-2-环己烯-1-基羟甲基] -5-甲基-6-氧杂-2-氮杂双环[3.2. 0]庚烷-3,7-二酮, NPI-0052, 盐孢酰胺A

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H20ClNO4
CAS號碼:
分子量::
313.78
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

生物源

(Salinospora tropica)

化驗

≥95% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

ClCC[C@@H]1[C@@]2(OC(=O)[C@@]2(NC1=O)[C@@H](O)[C@H]3CCCC=C3)C

InChI

1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1

InChI 密鑰

NGWSFRIPKNWYAO-SHTIJGAHSA-N

應用

Marizomib作为蛋白酶体抑制剂已用于:
  • 研究其对胶质母细胞瘤细胞系的影响
  • 分析其对鳉鱼脑老化的影响
  • 检测其对多发性骨髓瘤细胞中蛋白激酶B(PKB/AKT)水平的影响

生化/生理作用

Marizomib是一种具有抗癌活性的第二代蛋白酶体抑制剂。
Marizomib是一种具有抗癌活性的第二代蛋白酶体抑制剂。Marizomib能够不可逆地结合并有效抑制所有三种20S蛋白酶体亚基。
Marizomib(马里佐米)属于天然产物,是一种海洋生物来源的β-内酯-γ-内酰胺。它具有对血液和实体恶性肿瘤的治疗作用。它参与胱天蛋白酶3、8和9活化,增加活性氧(ROS)和促进细胞凋亡。Marizomib可穿过血脑屏障,是治疗原发脑肿瘤的潜力药物。它具有抗肿瘤特性。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Kaijun Di et al.
Neuro-oncology, 18(6), 840-848 (2015-12-19)
The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential
Nancy Levin et al.
British journal of haematology, 174(5), 711-720 (2016-05-11)
Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in
A M Rajan et al.
Blood cancer journal, 6(7), e451-e451 (2016-07-30)
The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務